2025-08-11 - Analysis Report
Okay, here's an analysis of Eli Lilly and Co (LLY) based on the provided data, presented in English with key numerical insights and interpretations:

## Eli Lilly and Co (LLY) Stock Analysis

**Company Overview:** Eli Lilly and Co is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

### 1. Performance vs. S&P 500 (VOO)

*   **Cumulative Return (LLY):** 200.86%
*   **Cumulative Return (VOO):** 84.01%
*   **Absolute Outperformance:** 109.1
*   **Relative Outperformance:** 38.1 (This means LLY's outperformance is positioned in the 38.1th percentile of its historical outperformance range.)

**Analysis:** LLY has significantly outperformed the S&P 500. The positive 'Relative Outperformance' indicates that the outperformance is above the median value, showing that the stock is not in downtrend with the S&P 500.

### 2. Alpha, Beta Analysis

| Year       | CAGR   | MDD   | Alpha  | Beta | Cap (B) |
|------------|--------|-------|--------|------|---------|
| 2015-2017  | 10.0%  | 56.3% | 8.0%   | 0.0  | 75.7    |
| 2016-2018  | 39.0%  | 58.6% | 43.0%  | 0.1  | 103.7   |
| 2017-2019  | 50.0%  | 58.6% | 27.0%  | 0.1  | 117.8   |
| 2018-2020  | 52.0%  | 58.6% | 25.0%  | 0.1  | 151.4   |
| 2019-2021  | 106.0% | 60.6% | 57.0%  | 0.0  | 247.6   |
| 2020-2022  | 98.0%  | 64.8% | 91.0%  | 0.1  | 328.0   |
| 2021-2023  | 133.0% | 64.8% | 113.0% | 0.2  | 522.6   |
| 2022-2024  | 150.0% | 72.2% | 123.0% | 0.2  | 692.1   |
| 2023-2025  | 54.0%  | 76.8% | 5.0%  | 0.2  | 560.9   |

**Analysis:**

*   **CAGR:**  Shows strong growth, but decreasing growth from 2022-2024 to 2023-2025.
*   **MDD:** Maximum Drawdown is increasing, but has the potential for significant losses in the stock price.
*   **Alpha:** Significantly positive, suggesting LLY's performance is not solely attributable to market movements. From 2022-2024, Alpha is decreased rapidly
*   **Beta:** Low Beta values mean that LLY has less volatility than the stock market, but from 2021, Beta is increased to 0.2.
*   **Market Cap:** The Market Cap has grown significantly, reflecting the company's growing value.

### 3. Recent Price Action

*   **Current Price:** 625.65
*   **Previous Close:** 640.86
*   **Change:** -2.37%
*   **5-Day Moving Average:** 709.566
*   **20-Day Moving Average:** 761.555
*   **60-Day Moving Average:** 765.3467

**Analysis:**

*   The stock price decreased by 2.37% compared to the previous close.
*   The current price is below all three moving averages, indicating a potential short-term downtrend. The gap between the short-term (5-day) and long-term (60-day) moving averages suggests the downtrend might have some momentum.
*   The negative change and the price being below moving averages confirm the short-term decline.

### 4. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3323 (Low Risk)
*   **RSI:** 26.89 (Oversold)
*   **PPO:** -2.07 (Negative, indicating bearish momentum)
*   **Hybrid Signal:** cash_68%_Sell 2.3% of holdings (4 shares - Caution - MRI:0.34)
*   **Recent (20-day) Relative Outperformance Change:** -4.1 (Negative, Short-term decline)
*   **Expected Return:** 256.1% (Long-term, vs. S&P 500)

**Analysis:**

*   **MRI:** Indicates a low risk environment overall, though the specific value might warrant caution.
*   **RSI:** The RSI is below 30, indicating that the stock is oversold and may be due for a rebound.
*   **PPO:** Negative PPO confirms bearish momentum.
*   **Hybrid Signal:** The hybrid signal suggests reducing holdings (selling 2.3%) and increasing cash position to 68%, likely as a cautionary measure given the recent price decline.
*   **Recent Outperformance Change:** Reinforces the short-term downward trend.
*   **Expected Return:** The exceptionally high expected return (256.1%) suggests that the model predicts significant outperformance relative to the S&P 500 over the long term, assuming a buy-and-hold strategy.

*   **Price Change Impact:** The fact that `{'price': 625.65, 'previousClose': 640.86, 'change': -2.37}` shows a notable decrease suggests a recent event or shift in sentiment that has negatively impacted the stock.

### 5. Recent News & Significant Events

*   **2025-08-10:** Major business developments, regulatory changes, or market events.
*   **2025-08-09:** Analyst discussions regarding recent performance, industry trends, and global economic factors.
*   **2025-08-08:** Stock volatility due to recent news, earnings reports, or executive actions.
*   **2025-08-11:** Market experts highlight risks and opportunities.

**Analysis:** The news snippets point to recent events impacting LLY, potentially including regulatory or market changes, recent earnings analysis, and industry trends and global economic factors.

### 6. Recent Earnings Analysis

| 날짜        | EPS  | 매출         |
|-------------|------|--------------|
| 2025-08-07  | 6.3  | 15.56 B$     |
| 2025-05-01  | 3.07 | 12.73 B$     |
| 2024-10-30  | 1.08 | 11.44 B$     |
| 2024-08-08  | 3.29 | 11.30 B$     |
| 2025-08-07  | 3.29 | 11.30 B$     |

**Analysis:**

*   The most recent EPS (6.3) is significantly higher than previous quarters.
*   Revenue has generally been increasing, with a notable jump in the most recent quarter (15.56 B$).
*   The strong EPS and Revenue in the latest quarter likely contributed to the positive long-term outlook, but more details are needed to assess sustainability.

### 7. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-06-30   | $15.56B    | 84.27%        |
| 2025-03-31   | $12.73B    | 82.53%        |
| 2024-12-31   | $13.53B    | 82.24%        |
| 2024-09-30   | $11.44B    | 81.02%        |
| 2024-06-30   | $11.30B    | 80.80%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE       |
|--------------|------------|-----------|
| 2025-06-30   | $18.27B    | 30.98%    |
| 2025-03-31   | $15.76B    | 17.50%    |
| 2024-12-31   | $14.19B    | 31.07%    |
| 2024-09-30   | $14.24B    | 6.81%     |
| 2024-06-30   | $13.56B    | 21.88%    |

**Analysis:**

*   **Revenue:** Steady growth in revenue over the past five quarters, culminating in a significant increase in the most recent quarter.
*   **Profit Margin:** Very high and stable profit margins, indicating strong efficiency and pricing power.
*   **Equity:** Growing equity base, which is a positive sign for the company's financial health.
*   **ROE:** Fluctuating ROE, but generally at a good level, reflecting the company's ability to generate profit from shareholders' equity. The high ROE in recent quarters is particularly noteworthy.

### 8. Overall Summary

Eli Lilly and Co (LLY) has exhibited strong performance, significantly outperforming the S&P 500 over the long term. Recent earnings and financial data show strong revenue growth and high profit margins. However, the recent price decline, negative momentum indicators (RSI, PPO), and the hybrid signal suggesting caution warrant careful consideration. The news flow suggests recent developments are impacting the stock, and investors should closely monitor company announcements and industry trends.

While the long-term expected return is very attractive, the current technical indicators point to a potential short-term downtrend. The recent data indicates that investors consider to reduce the holdings with cash to mitigate risk.
